Medicare Enrolled
Dr. Vikas Jain, M.D.
Cardiovascular Disease · Grapevine, TX
Practice pattern: Cardiac Imaging— Practice with significant diagnostic imaging and stress testing
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Jain from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Jain? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Jain
Dr. Vikas Jain is a cardiovascular disease in Grapevine, TX, with 20 years in practice. Based on federal Medicare data, Dr. Jain performed 9,306 Medicare services across 5,178 unique beneficiaries.
Between the years covered by Open Payments, Dr. Jain received a total of $292,997 from 57 pharmaceutical and/or device companies across 859 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in cardiovascular disease. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Jain is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice▲ Top 4% volume in TX$ $292,997 industry payments
Medicare Practice Summary
Medicare Utilization ↗9,306
Medicare services
Top 4% in TX for cardiovascular disease
5,178
Unique beneficiaries
$68
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~465 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Contrast dye for imaging (iodine-based) | 2,285 | $0 | $4 |
| Regadenoson injection (Lexiscan) for heart stress test | 1,332 | $42 | $217 |
| Office visit, established patient (30-39 min) | 814 | $89 | $238 |
| EKG interpretation and report | 728 | $6 | $30 |
| Electrocardiogram (EKG), 12-lead | 475 | $10 | $51 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 431 | $51 | $258 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 299 | $53 | $461 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 291 | $341 | $1,599 |
| Echocardiogram, transthoracic | 283 | $144 | $729 |
| Office visit, established patient (20-29 min) | 222 | $62 | $168 |
| Hospital follow-up visit, moderate complexity | 157 | $61 | $186 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 148 | $541 | $1,384 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 125 | $1,060 | $4,869 |
| New patient office visit (45-59 min) | 121 | $113 | $310 |
| Remote pacemaker/defibrillator monitoring, 90 days | 118 | $16 | $84 |
| Initial hospital admission, high complexity | 113 | $136 | $517 |
| Anticoagulant management of patient taking warfarin | 104 | $7 | $41 |
| Blood draw (venipuncture) | 92 | $8 | $17 |
| Remote pacemaker monitoring, 90 days | 91 | $21 | $109 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 66 | $2 | $28 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 59 | $11 | $53 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 59 | $26 | $75 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 58 | $18 | $95 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 57 | $16 | $79 |
| Prothrombin time test (blood clotting) | 53 | $4 | $26 |
| Ultrasound of heart with probe in esophagus, with report | 52 | $83 | $393 |
| Ultrasound of heart blood flow, valves and chambers | 49 | $14 | $65 |
| Ultrasound of both sides of head and neck blood flow | 45 | $139 | $704 |
| Hospital follow-up visit, high complexity | 41 | $90 | $268 |
| Office visit, established patient (10-19 min) | 36 | $36 | $105 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 34 | $17 | $95 |
| Initial hospital admission, moderate complexity | 34 | $103 | $352 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 33 | $18 | $98 |
| Injection, perflutren lipid microspheres, per ml | 32 | $37 | $271 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 31 | $9 | $96 |
| Telephone medical discussion with physician, 5-10 minutes | 31 | $40 | $131 |
| Programming of dual lead pacemaker system | 29 | $56 | $299 |
| External shock to heart to regulate heart beat | 26 | $73 | $707 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 26 | $23 | $181 |
| Telephone medical discussion with physician, 11-20 minutes | 25 | $68 | $212 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 21 | $6 | $155 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 20 | $10 | $128 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 18 | $14 | $85 |
| Hospital follow-up visit, low complexity | 18 | $39 | $101 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 17 | $162 | $858 |
| Heart muscle strain imaging | 17 | $28 | $139 |
| Cardiac catheterization | 17 | $208 | $1,035 |
| Ultrasound of heart, follow-up | 16 | $75 | $361 |
| New patient office visit (30-44 min) | 16 | $76 | $207 |
| Blood creatinine level | 14 | $5 | $31 |
| Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | 14 | $62 | $260 |
| Electrocardiogram (ecg) 2-day continuous | 13 | $14 | $105 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
7.5% high complexity
51.1% medium
41.3% routine
Industry Payment Transparency
Open Payments through 2024 ↗$292,997
Total received (2018-2024)
Avg $41,857/year across 7 years
Top 2% in TX for cardiovascular disease
57
Companies
859
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$261,412 (89.2%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$16,813 (5.7%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$14,771 (5.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$43,297
2023$20,093
2022$37,068
2021$38,756
2020$36,162
2019$58,990
2018$58,631
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Amgen Inc.
$128,439
Boehringer Ingelheim Pharmaceuticals, Inc.
$100,782
Lilly USA, LLC
$38,205
Edwards Lifesciences Corporation
$10,941
Inspire Medical Systems, Inc.
$1,385
Janssen Pharmaceuticals, Inc
$1,368
Abbott Laboratories
$1,301
Medtronic, Inc.
$1,023
Novartis Pharmaceuticals Corporation
$919
E.R. Squibb & Sons, L.L.C.
$888
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)
$800
AstraZeneca Pharmaceuticals LP
$792
PFIZER INC.
$751
Novo Nordisk Inc
$523
Merck Sharp & Dohme LLC
$518
Amarin Pharma Inc.
$511
Astellas Pharma US Inc
$439
GlaxoSmithKline, LLC.
$240
Esperion Therapeutics, Inc.
$232
SANOFI-AVENTIS U.S. LLC
$230
CVRx, Inc.
$206
Janssen Scientific Affairs, LLC
$181
UIH Solutions LLC
$167
Gilead Sciences, Inc.
$162
ABIOMED
$161
Medtronic USA, Inc.
$161
Kowa Pharmaceuticals America, Inc.
$145
JAZZ PHARMACEUTICALS INC.
$139
Alnylam Pharmaceuticals Inc.
$136
Regeneron Pharmaceuticals, Inc.
$123
GENZYME CORPORATION
$113
Lexicon Pharmaceuticals, Inc.
$112
Merck Sharp & Dohme Corporation
$96
Regeneron Healthcare Solutions, Inc.
$95
Bayer Healthcare Pharmaceuticals Inc.
$76
Boston Scientific Corporation
$73
Myocardial Solutions, Inc.
$69
Medtronic Vascular, Inc.
$57
Kaneka Pharma America LLC
$55
GE HEALTHCARE
$47
ARBOR PHARMACEUTICALS, INC.
$39
Actelion Pharmaceuticals US, Inc.
$32
Kiniksa Pharmaceuticals, Ltd.
$32
Daiichi Sankyo Inc.
$27
Ethicon US, LLC
$22
AGEPHA Pharma FZ LLC
$20
Cardiovascular Systems Inc.
$19
Lantheus Medical Imaging, Inc.
$19
Lundbeck LLC
$18
Azurity Pharmaceuticals, Inc.
$18
Chiesi USA, Inc.
$17
HeartFlow, Inc.
$15
BOSTON SCIENTIFIC CORPORATION
$14
Bardy Diagnostics, Inc.
$12
Allergan Inc.
$11
Medicure Pharma Inc.
$11
Osprey Medical Inc
$9
Top 3 companies account for 91.3% of total payments
Associated products mentioned in payments ›
AVEIR · Arcalyst · Arctic Front · Assurity Pacemaker · BENLYSTA · BRILINTA · BYSTOLIC · Barostim Neo System · BodyGuardian · CAMZYOS · CARDENE · CHANTIX · CONFIRM RX · Cardiac Mapping System · CareLink · Carnation Ambulatory Monitor · Confirm Rx · Corlanor · Coronary Orbital Atherectomy System · Definity · DyeVert · EDARBYCLOR · EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) · ELIQUIS · ENTRESTO · EVICEL Fibrin Sealant (Human) · Edarbi · Edarbyclor · Edwards SAPIEN 3 Ultra Transcatheter Heart Valve · Ellipse ICD · EnSite Precision Cardiac Mapping System · FARXIGA · FFRct · Fortify Assura · GALLANT · HeartMate 3 Left Ventricular Assist Device · INJECTAFER · INSPIRE · INVOKANA · Impella · Inpefa · JARDIANCE · JOT DX · KEVZARA · Kerendia · LATITUDE Communicator Power Supply · LEQVIO · LEXISCAN · LODOCO · LifeVest · Livalo · MICRA · MULTAQ · NA · NEXLETOL · NEXLIZET · NORTHERA · ONPATTRO · OPSUMIT · Ozempic · PRADAXA · PRALUENT · PRALUENT ALIROCUMAB INJECTION · PROMUS · Pacemakers · QUADRA ALLURE MP · RYBELSUS · Repatha · Rybelsus · SAPIEN 3 Ultra RESILIA · Solitaire · TRULICITY · TYRX · TactiCath Quartz CFA Catheter · VERQUVO · VYNDAQEL · Vascepa · Wegovy · XARELTO · XYWAV · ZEPBOUND · ZYPITAMAG · uCT
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (89%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in cardiovascular disease and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 2% for cardiovascular disease in TX.
Equivalent to $3,148 per 100 Medicare services performed
Geographic Context
Cardiovascular Diseases within 10 mi
337
Per 100K population
15.8
County median income
$81,905
Nearest hospital
BAYLOR SCOTT & WHITE MEDICAL CENTER GRAPEVINE
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Jain is a cardiac imaging specialist, with above-average Medicare volume (top 4% in TX), and high industry engagement (speaking/promotional, top 2%), with 20 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Jain experienced with contrast dye for imaging (iodine-based)?
Based on Medicare claims data, Dr. Jain performed 2,285 contrast dye for imaging (iodine-based) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Jain receive payments from pharmaceutical companies?
Yes. Dr. Jain received a total of $292,997 from 57 companies across 859 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Jain's costs compare to other cardiovascular diseases in Grapevine?
Dr. Jain's average Medicare payment per service is $68. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Jain) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Cardiovascular Diseases in Grapevine
Browse cardiovascular diseases in Grapevine ranked by procedure volume and transparency data.
Highest volume
Top Cardiovascular Diseases in TX
Cardiovascular Diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Cardiovascular Diseases in TX
Which TX cardiovascular diseases receive the most from drug and device companies.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc..
By company
Boehringer Ingelheim Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Boehringer Ingelheim Pharmaceuticals, Inc..
By company
Lilly USA, LLC Payments to Doctors
See all physicians who received payments from Lilly USA, LLC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology